Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rapt Therapeutics Inc
(NQ:
RAPT
)
1.090
-0.110 (-9.17%)
Streaming Delayed Price
Updated: 3:39 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rapt Therapeutics Inc
< Previous
1
2
3
4
5
Next >
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
November 12, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 11, 2024
Via
Benzinga
Crude Oil Down 3%; Aramark Posts Upbeat Earnings
November 11, 2024
Via
Benzinga
Exposures
Fossil Fuels
Nasdaq Moves Lower; Canaan Shares Surge
November 11, 2024
Via
Benzinga
RAPT Therapeutics: Q4 Earnings Insights
March 07, 2024
Via
Benzinga
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury
November 11, 2024
RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.
Via
Benzinga
Exposures
Product Safety
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results
November 11, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
November 11, 2024
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 06, 2024
Via
Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
November 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 02, 2024
Via
Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024
August 08, 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
August 08, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
June 03, 2024
Via
Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
May 21, 2024
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm
May 09, 2024
From
Schall Law
Via
GlobeNewswire
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
May 09, 2024
RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure.
Via
Benzinga
Exposures
Product Safety
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
May 09, 2024
Via
Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024
May 09, 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
May 09, 2024
Via
Benzinga
RAPT Therapeutics Reports First Quarter 2024 Financial Results
May 09, 2024
Company maintains solid cash position of $141.6 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
April 09, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks to Dump Before They Go to Zero
April 09, 2024
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.
Via
InvestorPlace
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
March 11, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023
March 07, 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 07, 2024
Company maintains solid cash position of $158.9 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
February 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Rivian Automotive Reports Q4 Loss, Joins Etsy, Lucid Group And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
February 22, 2024
U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday.
Via
Benzinga
What's Going On With RAPT Therapeutics Stock On Wednesday?
February 21, 2024
Latest developments in RAPT Therapeutics as FDA places clinical hold on Phase 2b trial for zelnecirnon in dermatitis and asthma. Stock rebounds and analyst downgrades.
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.